TrialsgrambetaRCTs are beautiful

NOAH-AFNET 6

2023

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High-Rate Episodes

In 2,536 patients with device-detected atrial high-rate episodes, edoxaban did not reduce cardiovascular death, stroke, or systemic embolism compared with placebo.

Result

Efficacy: Composite of cardiovascular death, stroke, or systemic embolismHR 0.81 (95% CI 0.60-1.08)

Safety: Death or major bleedingHR 1.31 (95% CI 1.02-1.67)

Below 1 favours edoxaban, above 1 favours placebo.

Event rates Edoxaban 3.2 vs placebo 4.0 per 100 patient-years (composite of cardiovascular death, stroke, or systemic embolism)

Also reported: Neutral.

Original publication
Subtopic
DOAC
Design
Double-blind placebo-controlled RCT, terminated early
Relevance
Important: one of several pillars.
Cited in
ESC 2024 AF
Source
Kirchhof P, et al. N Engl J Med. 2023;389(13):1167-1179.doi 10.1056/NEJMoa2303062

Discussion & critique

Stopped early for safety with a low event rate, so a small benefit cannot be fully excluded. Suggests anticoagulation of short atrial high-rate episodes causes net harm without documented AF.

Discussed in podcasts